Taken together, these findings indicated that FOXO3a negatively regulates VEGF-A/NRP1 and that dysregulated FOXO3a/VEGF-A/NRP1 signaling plays a critical role in disease progression in breast cancer. This evidence concerns the gene NRP1 and breast carcinoma.